Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft

被引:43
|
作者
Liu, E. H. [1 ]
Digon, B. J., III [1 ]
Hirshberg, B. [1 ]
Chang, R. [2 ]
Wood, B. J. [2 ]
Neeman, Z. [2 ]
Kam, A. [2 ]
Wesley, R. A. [3 ]
Polly, S. M. [4 ]
Hofmann, R. M. [5 ]
Rother, K. I. [1 ]
Harlan, D. M. [1 ]
机构
[1] NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Diagnost Radiol, Bethesda, MD 20892 USA
[3] NIH, Ctr Clin, Off Director, Bethesda, MD 20892 USA
[4] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[5] Univ Wisconsin, Dept Med, Madison, WI USA
关键词
Beta cell regeneration; C-peptide; Islet transplantation; Pancreas transplantation; Type; 1; diabetes; T-CELLS; MELLITUS; REGENERATION; HUMANS; GROWTH; AUTOIMMUNITY; ANTIBODIES; TURNOVER; ADULT; ONSET;
D O I
10.1007/s00125-009-1342-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We measured serum C-peptide (at least 0.167 nmol/l) in 54 of 141 (38%) patients with chronic type 1 diabetes and sought factors that might differentiate those with detectable C-peptide from those without it. Finding no differences, and in view of the persistent anti-beta cell autoimmunity in such patients, we speculated that the immunosuppression (to weaken autoimmune attack) and euglycaemia accompanying transplant-based treatments of type 1 diabetes might promote recovery of native pancreatic beta cell function. We performed arginine stimulation tests in three islet transplant and four whole-pancreas transplant recipients, and measured stimulated C-peptide in select venous sampling sites. On the basis of each sampling site's C-peptide concentration and kinetics, we differentiated insulin secreted from the individual's native pancreatic beta cells and that secreted from allografted beta cells. Selective venous sampling demonstrated that despite long-standing type 1 diabetes, all seven beta cell allograft recipients displayed evidence that their native pancreas secreted C-peptide. Yet even if chronic immunosuppression coupled with near normal glycaemia did improve native pancreatic C-peptide production, the magnitude of the effect was quite small. Some native pancreatic beta cell function persists even years after disease onset in most type 1 diabetic patients. However, if prolonged euglycaemia plus anti-rejection immunosuppressive therapy improves native pancreatic insulin production, the effect in our participants was small. We may have underestimated pancreatic regenerative capacity by studying only a limited number of participants or by creating conditions (e.g. high circulating insulin concentrations or immunosuppressive agents toxic to beta cells) that impair beta cell function. ClinicalTrials.gov NCT00246844 and NCT00006505.
引用
收藏
页码:1369 / 1380
页数:12
相关论文
共 50 条
  • [1] Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft
    E. H. Liu
    B. J. Digon
    B. Hirshberg
    R. Chang
    B. J. Wood
    Z. Neeman
    A. Kam
    R. A. Wesley
    S. M. Polly
    R. M. Hofmann
    K. I. Rother
    D. M. Harlan
    Diabetologia, 2009, 52 : 1369 - 1380
  • [2] Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes
    Simmons, Kimber M.
    Gottlieb, Peter A.
    Michels, Aaron W.
    CURRENT DIABETES REPORTS, 2016, 16 (10)
  • [3] New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement
    Couri, Carlos E. B.
    Malmegrim, Kelen C. R.
    Oliveira, Maria C.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] The Impact of Pancreatic Beta Cell Heterogeneity on Type 1 Diabetes Pathogenesis
    Benninger, Richard K. P.
    Dorrell, Craig
    Hodson, David J.
    Rutter, Guy A.
    CURRENT DIABETES REPORTS, 2018, 18 (11)
  • [5] Preventing type 1 diabetes development and preserving beta-cell function
    Mastrandrea, Lucy D.
    Quattrin, Teresa
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2022, 29 (04) : 386 - 391
  • [6] Beta cell function during rapamycin monotherapy in long-term type 1 diabetes
    Piemonti, L.
    Maffi, P.
    Monti, L.
    Lampasona, V.
    Perseghin, G.
    Magistretti, P.
    Secchi, A.
    Bonifacio, E.
    DIABETOLOGIA, 2011, 54 (02) : 433 - 439
  • [7] Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?
    Webster, Kierstin L.
    Mirmira, Raghavendra G.
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [8] Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes
    Kimber M. Simmons
    Peter A. Gottlieb
    Aaron W. Michels
    Current Diabetes Reports, 2016, 16
  • [9] Capturing residual beta cell function in type 1 diabetes
    Pociot, Flemming
    DIABETOLOGIA, 2019, 62 (01) : 28 - 32
  • [10] Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
    Wentworth, John M.
    Bediaga, Naiara G.
    Giles, Lynne C.
    Ehlers, Mario
    Gitelman, Stephen E.
    Geyer, Susan
    Evans-Molina, Carmella
    Harrison, Leonard C.
    DIABETOLOGIA, 2019, 62 (01) : 33 - 40